FibroBiologics, Inc. (FBLG)
NASDAQ: FBLG · IEX Real-Time Price · USD
11.35
-0.45 (-3.81%)
May 17, 2024, 4:30 PM EDT - Market closed
Company Description
FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company.
It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials.
It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.
FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.
FibroBiologics, Inc.
Country | United States |
Founded | 2021 |
IPO Date | Jan 31, 2024 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 10 |
CEO | Peter O'Heeron |
Contact Details
Address: 455 E. Medical Center Blvd, Suite 300 Houston, Texas 77598 United States | |
Phone | 281-671-5152 |
Website | fibrobiologics.com |
Stock Details
Ticker Symbol | FBLG |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $30.00 |
CIK Code | 0001958777 |
Employer ID | 86-3329066 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Peter O'Heeron | Founder, Chairman and Chief Executive Officer |
Mark C. Andersen C.F.A., CPA, M.B.A. | Chief Financial Officer |
Dr. Hamid Khoja Ph.D. | Chief Scientific Officer |
Ruben A. Garcia | General Counsel |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 15, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
May 15, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
May 14, 2024 | 10-Q | Quarterly Report |
Apr 26, 2024 | 8-K | Current Report |
Apr 26, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
Apr 12, 2024 | DRS | [Cover] Draft Registration Statement |
Mar 28, 2024 | EFFECT | Notice of Effectiveness |
Mar 28, 2024 | 424B4 | Prospectus |
Mar 26, 2024 | S-1/A | [Amend] General form for registration of securities under the Securities Act of 1933 |
Mar 25, 2024 | UPLOAD | Filing |